Cargando…
Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
Over the past decade, the development of new targeted therapeutics directed against specific molecular pathways involved in tumor cell proliferation and survival has allowed an essential improvement in carcinoma treatment. Unfortunately, the scenario is different for sarcomas, a group of malignant n...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601986/ https://www.ncbi.nlm.nih.gov/pubmed/28955656 http://dx.doi.org/10.3389/fonc.2017.00203 |
_version_ | 1783264499597312000 |
---|---|
author | Gaebler, Manuela Silvestri, Alessandra Haybaeck, Johannes Reichardt, Peter Lowery, Caitlin D. Stancato, Louis F. Zybarth, Gabriele Regenbrecht, Christian R. A. |
author_facet | Gaebler, Manuela Silvestri, Alessandra Haybaeck, Johannes Reichardt, Peter Lowery, Caitlin D. Stancato, Louis F. Zybarth, Gabriele Regenbrecht, Christian R. A. |
author_sort | Gaebler, Manuela |
collection | PubMed |
description | Over the past decade, the development of new targeted therapeutics directed against specific molecular pathways involved in tumor cell proliferation and survival has allowed an essential improvement in carcinoma treatment. Unfortunately, the scenario is different for sarcomas, a group of malignant neoplasms originating from mesenchymal cells, for which the main therapeutic approach still consists in the combination of surgery, chemotherapy, and radiation therapy. The lack of innovative approaches in sarcoma treatment stems from the high degree of heterogeneity of this tumor type, with more that 70 different histopathological subtypes, and the limited knowledge of the molecular drivers of tumor development and progression. Currently, molecular therapies are available mainly for the treatment of gastrointestinal stromal tumor, a soft-tissue malignancy characterized by an activating mutation of the tyrosine kinase KIT. Since the first application of this approach, a strong effort has been made to understand sarcoma molecular alterations that can be potential targets for therapy. The low incidence combined with the high level of histopathological heterogeneity makes the development of clinical trials for sarcomas very challenging. For this reason, preclinical studies are needed to better understand tumor biology with the aim to develop new targeted therapeutics. Currently, these studies are mainly based on in vitro testing, since cell lines, and in particular patient-derived models, represent a reliable and easy to handle tool for investigation. In the present review, we summarize the most important models currently available in the field, focusing in particular on the three-dimensional spheroid/organoid model. This innovative approach for studying tumor biology better represents tissue architecture and cell–cell as well as cell–microenvironment crosstalk, which are fundamental steps for tumor cell proliferation and survival. |
format | Online Article Text |
id | pubmed-5601986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56019862017-09-27 Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management Gaebler, Manuela Silvestri, Alessandra Haybaeck, Johannes Reichardt, Peter Lowery, Caitlin D. Stancato, Louis F. Zybarth, Gabriele Regenbrecht, Christian R. A. Front Oncol Oncology Over the past decade, the development of new targeted therapeutics directed against specific molecular pathways involved in tumor cell proliferation and survival has allowed an essential improvement in carcinoma treatment. Unfortunately, the scenario is different for sarcomas, a group of malignant neoplasms originating from mesenchymal cells, for which the main therapeutic approach still consists in the combination of surgery, chemotherapy, and radiation therapy. The lack of innovative approaches in sarcoma treatment stems from the high degree of heterogeneity of this tumor type, with more that 70 different histopathological subtypes, and the limited knowledge of the molecular drivers of tumor development and progression. Currently, molecular therapies are available mainly for the treatment of gastrointestinal stromal tumor, a soft-tissue malignancy characterized by an activating mutation of the tyrosine kinase KIT. Since the first application of this approach, a strong effort has been made to understand sarcoma molecular alterations that can be potential targets for therapy. The low incidence combined with the high level of histopathological heterogeneity makes the development of clinical trials for sarcomas very challenging. For this reason, preclinical studies are needed to better understand tumor biology with the aim to develop new targeted therapeutics. Currently, these studies are mainly based on in vitro testing, since cell lines, and in particular patient-derived models, represent a reliable and easy to handle tool for investigation. In the present review, we summarize the most important models currently available in the field, focusing in particular on the three-dimensional spheroid/organoid model. This innovative approach for studying tumor biology better represents tissue architecture and cell–cell as well as cell–microenvironment crosstalk, which are fundamental steps for tumor cell proliferation and survival. Frontiers Media S.A. 2017-09-11 /pmc/articles/PMC5601986/ /pubmed/28955656 http://dx.doi.org/10.3389/fonc.2017.00203 Text en Copyright © 2017 Gaebler, Silvestri, Haybaeck, Reichardt, Lowery, Stancato, Zybarth and Regenbrecht. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Gaebler, Manuela Silvestri, Alessandra Haybaeck, Johannes Reichardt, Peter Lowery, Caitlin D. Stancato, Louis F. Zybarth, Gabriele Regenbrecht, Christian R. A. Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management |
title | Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management |
title_full | Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management |
title_fullStr | Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management |
title_full_unstemmed | Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management |
title_short | Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management |
title_sort | three-dimensional patient-derived in vitro sarcoma models: promising tools for improving clinical tumor management |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601986/ https://www.ncbi.nlm.nih.gov/pubmed/28955656 http://dx.doi.org/10.3389/fonc.2017.00203 |
work_keys_str_mv | AT gaeblermanuela threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement AT silvestrialessandra threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement AT haybaeckjohannes threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement AT reichardtpeter threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement AT lowerycaitlind threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement AT stancatolouisf threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement AT zybarthgabriele threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement AT regenbrechtchristianra threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement |